Clene Inc.
- Last sale
- Nov 12, 2026 · -1.07%
- Market cap
- $59.83M
- 14.4M shares
- Filings
- 715
Q3 2026−41.5% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY21 yoy
Q3 2026−57.3% FY25 yoy
- $59.83M
- —
- 251.4×
- —
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $200,000 | reported | |
| FY 2024 | 2024-12-31 | $342,000 | reported | |
| FY 2023 | 2023-12-31 | $654,000 | reported | |
| FY 2022 | 2022-12-31 | $473,000 | reported | |
| FY 2021 | 2021-12-31 | $723,000 | reported | |
| FY 2020 | 2020-12-31 | $206,000 | reported |
Segments
LineFY2022ShareChange
Supplements Segment$473.00K100%−34.6%
Drugs Segment$0.00——
Total$473.00K
Pharmaceutical preparations
Clene Inc. is the 238th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
PVCTProvectus Biopharmaceuticals, Inc.$336.1K45.5%1,615.8%$29.2MALLRAllarity Therapeutics, Inc.$320.0K—3,509.7%$14.7MHINDVyome Holdings, Inc$319.7K96.0%3,209.7%$11.1MABVCAbvc Biopharma, Inc.$296.0K41.9%2,671.8%$26.2MGDTCCytoMed Therapeutics Ltd$252.3K395.9%1,227.1%$9.8MRGBPRegen BioPharma Inc$236.6K0.0%538.8%$393.7K
CLNNClene Inc. (this company)$200.0K41.5%13,086.5%$59.8M
LSTALisata Therapeutics, Inc.$170.0K83.0%9,756.5%$13.0MSERSerina Therapeutics, Inc.$130.0K132.1%14,755.4%$37.7MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Clene Inc. · CIK 1822791 · Engraved from SEC EDGAR